Eton Pharmaceuticals (ETON) Accounts Payables (2017 - 2026)

Eton Pharmaceuticals has disclosed Accounts Payables across 10 years of filings, most recently posting $14.4 million for Q2 2026.

• In Q2 2026, Accounts Payables rose 18.64% year-over-year to $14.4 million; the TTM figure through Jun 2026 stood at $14.4 million (up 18.64% YoY), while the FY2025 annual figure was $11.0 million, up 163.4% from the prior year.
• Accounts Payables came in at $14.4 million for Q2 2026 at Eton Pharmaceuticals, up from $11.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $14.4 million in Q2 2026 to a low of $1.1 million in Q3 2022.
• Average Accounts Payables over 5 years is $4.8 million, with a median of $2.3 million recorded in 2024.
• Year-over-year, Accounts Payables tumbled 67.8% in 2022 and surged 469.25% in 2025.
• Over 5 years, Accounts Payables stood at $1.8 million in 2022, then gained by 4.64% to $1.8 million in 2023, then soared by 125.49% to $4.2 million in 2024, then soared by 163.4% to $11.0 million in 2025, then surged by 31.24% to $14.4 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $14.4 million in Q2 2026, $11.0 million in Q4 2025, and $14.3 million in Q3 2025.